Bellier, Charlotte
Gladieff, Laurence
Le Du, Fanny
Berton, Dominique
Bonnard, Charlotte
Suau, Delphine
Richard, Anne-Céline
Brenner, Ophélie
Lahouegue, Amir
Freyer, Gilles
Floquet, Anne
Frank, Sophie
Kfoury, Maria
Funding for this research was provided by:
AstraZeneca
Article History
Accepted: 11 December 2022
First Online: 11 January 2023
Declarations
:
: The work was funded by AstraZeneca France (part of an alliance between AstraZeneca and Merck Sharp & Dohme (MSD)).
: CB, DB and CF declare no conflicts of interest. LG declares honoraria and consulting/advisory board work for AstraZeneca. FL declares honoraria for consulting or advisory board work for Daiichi Sankyo, Lilly, Seagen, Novartis, Pfizer, Roche and Sandoz and travel fees from Daiichi Sankyo, Lilly, Novartis, Pfizer and Pierre Fabre and serves as a speaker for Amgen, Lilly, Novartis and Pierre Fabre. GF declares honoraria and advisory board work for AstraZeneca, BMS, Clovis Oncology, GSK, Lilly, MSD, Novartis and Pfizer. AF declares honoraria and congress and presentation work for AstraZeneca, GSK and Clovis Oncology. MK declares honoraria as a speaker for AstraZeneca and consultancy work for GSK.
: Not applicable. The ATUc programme is not a clinical trial and thus does not require ethics approval.
: Not applicable. The ATUc programme is not a clinical trial and therefore patient consent was not required. The patients did receive a patient information leaflet.
: Not applicable.
: Not applicable.
: Not applicable.
: The ATUc programme is not a clinical trial. Therefore, there is no study conception, design or material preparation. However all authors contributed to the data collection and analysis and writing of the article and the current version is approved by all authors.